Cortice Biosciences reports initial results from a Phase I/II trial of TPI 287 to treat recurrent Glioblastoma
These results will be presented in a poster presentation this evening at 7:30 PM ET at the 19th Annual Scientific Meeting and Education Day of the Society for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.